Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Gross Margin (2016 - 2025)

Historic Gross Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to 59.01%.

  • Ani Pharmaceuticals' Gross Margin rose 15300.0% to 59.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.14%, marking a year-over-year increase of 13500.0%. This contributed to the annual value of 59.27% for FY2024, which is 34400.0% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Gross Margin stood at 59.01% for Q3 2025, which was up 15300.0% from 64.7% recorded in Q2 2025.
  • Ani Pharmaceuticals' Gross Margin's 5-year high stood at 64.7% during Q2 2025, with a 5-year trough of 78.44% in Q1 2021.
  • Moreover, its 5-year median value for Gross Margin was 59.01% (2025), whereas its average is 51.06%.
  • In the last 5 years, Ani Pharmaceuticals' Gross Margin tumbled by -1346300bps in 2021 and then soared by 1252900bps in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Gross Margin (Quarter) stood at 44.36% in 2021, then soared by 39bps to 61.45% in 2022, then decreased by -3bps to 59.42% in 2023, then fell by -3bps to 57.87% in 2024, then grew by 2bps to 59.01% in 2025.
  • Its last three reported values are 59.01% in Q3 2025, 64.7% for Q2 2025, and 62.95% during Q1 2025.